A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Status Not yet recruiting

Clinical Trial Summary

This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 21 days.

Clinical Trial Description

During the phase I study, the safety and tolerability of HB0045 will be evaluated in patients with advanced solid tumors including understanding of the preliminary efficacy. During this phase of the study, DLTs, MTD and MTD range will be observed which will inform RP2D. Phase I:Approximately 54 patients will receive HB0045 as a monotherapy at escalating doses.One cycle is defined as 3 weeks (21 days). In the phase II study, the safety and preliminary efficacy of HB0045 at the RP2D will be evaluated in cohorts of patients with pancreatic, colorectal, ovarian cancer and/or other solid tumors.Phase II:During the dose escalation process, expansion cohorts will be conducted based on the preliminary RP2D.A Simon 2-stage design will be utilized with a stopping rule to allow for early termination of a particular cohort at the end of Stage 1 if patients have insufficient responses to HB0045. During Stage 1, 9 evaluable patients will be enrolled in each cohort; if no responses are observed within the cohort, then the cohort will be discontinued. If at least 1 response is observed, 8 additional evaluable patients will be enrolled in the cohort (Stage 2), for a maximum of 17 evaluable patients per cohort. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05944276
Study type	Interventional
Source	Huabo Biopharm Co., Ltd.
Contact	Nashat Gabrail
Phone	330-492-3345
Email	ngabrailmd@gabrailcancercenter.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	August 20, 2023
Completion date	March 19, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04551885` - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1
Completed	`NCT05054348` - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04474470` - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	Phase 1/Phase 2
Recruiting	`NCT06088004` - Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Completed	`NCT04020185` - Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Phase 1/Phase 2
Withdrawn	`NCT05071846` - MVX-ONCO-2 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05607199` - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics	Phase 1
Active, not recruiting	`NCT04552288` - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies	Phase 2
Active, not recruiting	`NCT06026254` - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial	Phase 1
Recruiting	`NCT06032845` - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)	Phase 2
Recruiting	`NCT06144671` - GT201 Injection For The Treatment Of Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06398418` - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors	Phase 1
Recruiting	`NCT05276284` - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy	Phase 1/Phase 2
Recruiting	`NCT04121442` - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04221204` - A Monotherapy in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT03992326` - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors	Phase 1
Terminated	`NCT05435339` - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy	Phase 1/Phase 2
Recruiting	`NCT04981119` - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting	`NCT06075849` - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent	Phase 1